Diffusion Genome Privacy - SHCS App (mobile_app) Browse

genopri-shcs/project/migrationTools/migr_sqlite/dump_client/insert_tests.sql
faa7327c8c80mobile_app

insert_tests.sql
View Options

			--
			-- Dumping data for table 'tests'
			--
			INSERT INTO 'tests' VALUES (1,'HIV ACQUISITION','A 32 basepair deletion in the CCR5 gene associates with both slower disease progression (when 1 copy is present) and resistance to infection by R5-tropic strains of HIV (when 2 copies are present).','HIV/HCV'),(2,'HIV PROGRESSION','Variants in class I HLA genes (in particular HLA-B and HLA-C) and in CCR5 have been shown to associate with reduced viral load and slower disease progression off therapy. With one minor allele at rs2395029 or any two minor alleles except in the case of CCR5d32 homozygosity.','HIV/HCV'),(3,'ABC HYPERSENSITIVITY','Hypersensitivity reaction while on Abacavir is tightly correlated with the presence of the classical class I HLA-B allele *57:01.','HIV/HCV'),(4,'ATV HYPERBILIRUBINEMIA','Carrying two copies of a deleterious allele in the UGT1A1 gene has been shown to increase the likelihood of jaundice while on antiretroviral therapy and can lead to treatment discontinuation. Risk is reported when two risk alleles are present.','HIV/HCV'),(5,'HCV CLEARANCE','Variants in/near the IL-28B gene have been repeatedly shown to associate with spontaneous resolution of HCV infection. Carrying one C allele at rs12979860 results in a modest increase in the likelihood of clearance whereas carrying two copies greatly increases the chances of clearance.','HIV/HCV'),(6,'HCV INF RESPONSE','Variants in/near the IL-28B gene have been repeatedly shown to associate with increased response to interferon therapy in HCV infected patients. Carrying one C allele at rs12979860 results in a modest increase in the likelihood of response to interferon whereas carrying two copies greatly increases the chances of response to interferon.','HIV/HCV'),(7,'HCV ANAEMIA','Variants in/near the ITPA gene have been shown to associate with the development of anaemia in HCV patients while on Ribavirin. Protection against anaemia reported in patients carrying one or more C alleles at rs6051702.','HIV/HCV'),(8,'EFV PHARMACOKINETICS_CYP2B6','Variants in the CYP2B6 gene have been shown to associate with increased plasma levels of EFV in HIV patients. Additionally, carrying two deleterious alleles in CYP2B6 and a rare allele in CYP2A6 may result in extremely high plasma levels and risk of treatment discontinuation. With 2 risk alleles in CYP2B6 the pharmacokinetic result is reported. If the patient has 2 risk alleles in CYP2B6 and one or more risk alleles in CYP2A6 the risk of treatment discontinuation is reported.','Pharmacokinetics'),(9,'NVP PHARMACOKINETICS','Variants in the CYP2B6 gene have been shown to associate with increased plasma levels of NVP in HIV patients. With 2 risk alleles in CYP2B6 the result is reported.','Pharmacokinetics'),(10,'ETV PHARMACOKINETICS','Rare, functional variants in CYP2C9 and CYP2C19 have been shown to associate with increased plasma levels of ETV in HIV patients. With any risk alleles in either gene the result is reported.','Pharmacokinetics'),(11,'LPV PHARMACOKINETICS','Variants in SLCO1B1 have been associated with both increased and decreased plasma levels of LPV. Additionally, variants in ABCC2 and CYP3A contribute to high plasma levels. Alleles across the four SNPs are counted with a score of +1 given for each allele at rs717620, rs6945984, rs4149056 and -1 given for each allele at rs17329885. If the patients score is >=2 risk of high plasma levels is reported, if the score =-2 risk of low plasma levels is reported.','Pharmacokinetics'),(12,'CORONARY ARTERY DISEASE','Multiple studies have uncovered genetic variants that increase risk of CAD. Additionally, HIV+ individuals in the highest genetic risk category have been shown to be more likely to develop CAD. The reported result is based on an additive genetic score. For each patient, the number of alleles at each SNP is multiplied by the weight for that SNP. These weighted values are then summed across all SNPs to calculate the patient’s final risk score. For patients falling in the highest risk category (additive score>2.74) the result is reported.','Metabolic Disorders'),(13,'NON-HDL CHOLESTEROL','Genome-wide association studies have reliably associated several variants impacting traits of dyslipidemia. In HIV+ individuals treated with ART, the weight of the contribution of common SNPs and ART to dyslipidemia was similar. An additive genetic score is calculated per patient by summing the alleles across all SNPs. Each risk allele is given a score of +1 and each protective allele a score of -1. If the sum across all alleles is >1 the result is reported.','Metabolic Disorders'),(14,'HDL CHOLESTEROL','An additive genetic score is calculated per patient by summing the alleles across all SNPs. Each risk allele is given a score of +1 and each protective allele a score of -1. If the sum across all alleles is >2 the result is reported','Metabolic Disorders'),(15,'TRIGLYCERIDES','An additive genetic score is calculated per patient by summing the alleles across all SNPs. Each risk allele is given a score of +1 and each protective allele a score of -1. If the sum across all alleles is >1 the result is reported.','Metabolic Disorders'),(16,'TYPE 2 DIABETES','Metabolic complications, including Type 2 Diabetes, are a major long-term concern in HIV+ individuals. In HIV+ patients treated with antiretroviral therapy, the Type 2 Diabetes effect of genetic variants was observed to be larger than the potential toxic effects of antiretroviral therapy.','Metabolic Disorders'),(17,'VITAMIN D DEFICIENCY','Vitamin D deficiency is highly prevalent in HIV-infected individuals. In a population pharmacokinetic model, patients homozygous for the rare allele at rs2282679 presented 25(OH)D plasma levels 25% lower than reference and heterozygous individuals.','Metabolic Disorders'),(201,'HIV PROGRESSION','Variants in class I HLA genes (in particular HLA-B and HLA-C) and in CCR5 have been shown to associate with reduced viral load and slower disease progression off therapy. With one minor allele at rs2395029 or any two minor alleles except in the case of CCR5d32 homozygosity.','HIV/HCV'),(801,'EFV PHARMACOKINETICS_CYP2A6','Variants in the CYP2B6 gene have been shown to associate with increased plasma levels of EFV in HIV patients. Additionally, carrying two deleterious alleles in CYP2B6 and a rare allele in CYP2A6 may result in extremely high plasma levels and risk of treatment discontinuation. With 2 risk alleles in CYP2B6 the pharmacokinetic result is reported. If the patient has 2 risk alleles in CYP2B6 and one or more risk alleles in CYP2A6 the risk of treatment discontinuation is reported. An additive genetic score is calculated per patient by summing the alleles across all SNPs. Each risk allele is given a score of +1 and each protective allele a score of -1. If the sum across all alleles is >6 the result is reported.','Pharmacokinetics');
			-- Dump completed on 2014-07-10 10:13:36